Diabetes

The American Diabetes Association guidelines have self-care and lifestyle recommendations for patients and health care professionals.

Lifestyle modifications are the cornerstone of treatment.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

Semaglutide (Wegovy) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients.

Stephanie Mason believes that pharmacists should expect their involvement in glycemic management to increase in the near future.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Appropriate screening tools can help identify individuals at increased risk for or with anxiety, depression, and eating disorders.

Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Kombiglyze is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Individuals with elevated arterial stiffness combined with high blood pressure had the highest risk of developing type 2 diabetes.

The FreeStyle Libre 3 is the most accurate 14-day continuous glucose monitor with a 7.9% overall mean absolute relative difference and readings are sent directly to a smartphone every minute.

Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.

Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The measures will also affect workers across all areas of the hospital, including dietitians, information technology, nurses, and physicians.

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise in adults with type 2 diabetes.

Investigators analyzed data from nearly 4000 individuals from the National Longitudinal Study of Adolescent to Adult Health.

Individuals with type 2 diabetes who use insulin are often restricted when accessing continuous glucose monitoring systems.

Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Spending 1 hour less sitting a day and increasing light physical activity helps prevent diseases, investigators find.

Pharmacists are well suited to help patients overcome the barriers that prevent access to therapy regimens.